Needham & Company
-
ResMed (RMD) Gains Over 17% on FQ2 Earnings Beat, Ratings Upgrades and Price Target Boost
-
Needham & Company Upgrades ResMed (RMD) to Hold
-
ResMed (RMD): SAVE Results A Negative Headline With Delayed Importance - Needham
-
Notable Analyst Rating Changes 6/27: (GOLD) (GME) (ALXN) Upgraded; (RMD) (PCAR) (LYB) Downgraded
-
Needham & Company Downgrades ResMed (RMD) to Underperform
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Needham & Company Downgrades ResMed (RMD) to Hold
-
ResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4
-
Needham & Company Reiterate Buy Following ResMed (RMD) Investor Meeting
-
Notable Analyst Rating Changes 1/23: (LNKD) (LULU) (CHK) Upgraded; (X) (DWA) (XOM) Downgraded
-
Needham & Company Upgrades ResMed (RMD) to Buy
-
Needham & Company Starts ResMed (RMD) at Hold
-
Notable Analyst rating Changes for 02/05: RMD, WFR, ALKS, SFN, BEBE Upgraded; FWD, EGOV, LEAP, COH, CIEN Downgraded
-
Morning Movers 2/5: ARG, KOOL, PWER, BEBE, END Higher; PFWD, EGOV, INPH, N, PTEC Lower